Catabasis is a private, venture-backed biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids and other clinically validated compounds to create new medicines for the treatment of inflammatory and metabolic diseases. The company’s lead compound for the treatment of inflammatory diseases and type 2 diabetes is in clinical trials.